Income Taxes (Details) - USD ($) |
8 Months Ended | 9 Months Ended | 12 Months Ended |
|---|---|---|---|
Dec. 31, 2020 |
Sep. 30, 2022 |
Dec. 31, 2021 |
|
| Income Tax Disclosure [Abstract] | |||
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | $ 808,821 | $ 4,132,018 | |
| Net operating loss carryforwards | 12,468,027 | ||
| Federal net operating losses carryforward | 13,221,253 | ||
| Research and development | 91,217 | ||
| Federal research tax credit carryforwards | $ 208,150 | ||
| Net operating loss term | 5 years | ||
| Taxable income net operating losses | 80.00% | ||
| Provision for income taxes | $ 0 | $ 0 | |
| Unrecognized tax benefits | $ 0 |
| X | ||||||||||
- Definition Amount of federal operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. No definition available.
|
| X | ||||||||||
- Definition Federal research tax credit carryforwards. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Taxable income net operating losses. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|